Clal Insurance Enterprises Holdings

Clal Insurance Enterprises Holdings Ltd. is a prominent insurance and financial services provider based in Tel Aviv, Israel, established in 1987. The company operates through three main segments: Long-Term Savings, Non-Life Insurance, and Health Insurance. Its Long-Term Savings segment offers a range of life insurance products, pension plans, and provident funds. The Non-Life Insurance segment provides various coverage options, including property, motor vehicle, liability, and credit insurance, catering to both individual and business customers. The Health Insurance segment delivers comprehensive services such as hospitalization, long-term care, personal accident, and travel insurance for individuals and groups. Clal Insurance primarily serves private clients, policyholders, and self-employed workers, emphasizing a diverse portfolio of insurance solutions tailored to meet different needs.

Yoram Naveh

CEO

18 past transactions

Beyond Oil

Post in 2025
Beyond Oil is a food-tech company that specialises in the production, development, and design of filtering and processing aid products for food-service businesses. Beyond Oil delivers cutting-edge solutions that enhance efficiency in food processing committed to transforming culinary experiences. The company plays a crucial role in elevating the quality and sustainability of food preparation and deliver a healthier final product by reducing the formation of carcinogenic substances in fried food.

Bet Shemesh Engines Holdings

Post in 2024
Bet Shemesh Engines is a manufacturer of engine parts that provides turbine engine parts and services to its customer base. They provide maintenance, repair, overhaul, and engineering services to complete engines as well as to modules and engine components and accessories.

Simplilearn

Series E in 2022
Simplilearn is an online education platform that specializes in providing digital skills training and certification courses for professionals worldwide. Catering to young working professionals, the company offers over 200 courses across various industry verticals, including cybersecurity, cloud computing, project management, digital marketing, and business leadership. With a blended delivery model and a commitment to customer satisfaction, Simplilearn aims to empower individuals to enhance their careers through recognized certifications. The company has trained more than 400,000 professionals in over 150 countries and has received accolades for its rapid growth and educational excellence. As a registered education provider for several prestigious organizations, Simplilearn continues to focus on delivering high-quality training content and innovative technology solutions to support professional development.

Diagnostic Robotics

Series B in 2022
Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

Pyramid Analytics

Series E in 2022
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Learn more www.pyramidanalytics.com

Max

Acquisition in 2022
Max issues credit cards and offers clearing services. Its products include Multi, Leumi Card Free, Cash Card, and World Signia. Max also provides Gift Card, Y-Card, and Visa Plus in Israel. Moreover, it offers services for organizations and workplaces, merchant acquiring services, and credit solutions that include loans, payment discounts, multi-business, acquisition cards, and supplier cards. Max began operation in 2000, with its headquarters in Bnei Brak in Israel. It operates as a subsidiary of Bank Leumi Le-Israel BM.

Shopic

Series B in 2022
Shopic is a technology company focused on enhancing the grocery shopping experience for medium and large stores. It has developed a cloud-based platform that integrates artificial intelligence into traditional shopping carts, transforming them into smart carts capable of accurately recognizing products through advanced computer vision. This innovation not only streamlines the shopping journey but also serves as a dynamic retail media channel, offering personalized promotions to customers at the right time. By enabling cashier-less checkout systems, Shopic empowers grocery stores to modernize their operations and improve customer satisfaction.

MeMed

Venture Round in 2022
MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

Bluewhite

Series B in 2021
Blue White Robotics specializes in transforming agriculture through autonomous technology. The company offers a comprehensive platform that enhances both air and ground robot fleets, enabling seamless management and optimization. By leveraging remote sensing and artificial intelligence, Blue White Robotics provides farmers with in-field data to improve productivity and farm economics. Their solutions aim to enhance efficiency and safety while delivering actionable insights that contribute to a return on investment from the outset. The company's focus is on facilitating the easy and safe adoption of autonomy in agriculture, ultimately helping growers maximize productivity and reduce operational costs.

Silk

Series B in 2021
Silk specializes in enhancing AI innovation by providing real-time access to production data in the cloud. The company seamlessly integrates high-performance cloud storage into AI workflows, allowing organizations to improve their innovation processes while ensuring performance, reliability, and control over their enterprise data. Silk's agile data delivery system eliminates the need for copying production data, thereby increasing flexibility and enabling the use of production data for Generative AI applications. With a portfolio backed by over 20 technology patents, Silk assists customers in maximizing the capabilities of the public cloud efficiently. The company is headquartered near Boston, Massachusetts.

IRP Systems

Series C in 2021
IRP Systems specializes in electric motion technology for aviation and industrial robots, as well as e-mobility platforms. Founded in 2015 and headquartered in Ness Ziona, Israel, the company develops high-performance electric powertrain technology that incorporates proprietary control algorithms and innovative motor designs. Their Hummingbird Motion Systems deliver an exceptional size, weight, and power ratio, ensuring efficiency and effectiveness in electric motion applications. Additionally, IRP's TrueDrive product portfolio enhances the driving experience while maintaining cost-effectiveness and compliance with mass-production standards. Prior to its focus on e-mobility, IRP Systems successfully developed and certified motion systems for safety-critical aerospace applications.

Pagaya

Series D in 2020
Pagaya is a financial technology company that is transforming the asset management and lending marketplaces through the use of machine learning and big data analytics. It focuses on managing institutional money, particularly in fixed income and alternative credit, offering discretionary funds to institutions such as pension funds, insurance companies, and banks. Pagaya utilizes its proprietary technology platform, Pagaya Pulse, which employs advanced artificial intelligence algorithms to enhance performance and scalability. Additionally, Pagaya aims to improve the credit industry by providing a comprehensive solution that enhances customer experience and accessibility to credit, integrating seamlessly into its network of partners through a proprietary API. The company primarily generates its revenue from the United States.

Pagaya

Series C in 2019
Pagaya is a financial technology company that is transforming the asset management and lending marketplaces through the use of machine learning and big data analytics. It focuses on managing institutional money, particularly in fixed income and alternative credit, offering discretionary funds to institutions such as pension funds, insurance companies, and banks. Pagaya utilizes its proprietary technology platform, Pagaya Pulse, which employs advanced artificial intelligence algorithms to enhance performance and scalability. Additionally, Pagaya aims to improve the credit industry by providing a comprehensive solution that enhances customer experience and accessibility to credit, integrating seamlessly into its network of partners through a proprietary API. The company primarily generates its revenue from the United States.

MeMed

Series C in 2018
MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

Pagaya

Series B in 2018
Pagaya is a financial technology company that is transforming the asset management and lending marketplaces through the use of machine learning and big data analytics. It focuses on managing institutional money, particularly in fixed income and alternative credit, offering discretionary funds to institutions such as pension funds, insurance companies, and banks. Pagaya utilizes its proprietary technology platform, Pagaya Pulse, which employs advanced artificial intelligence algorithms to enhance performance and scalability. Additionally, Pagaya aims to improve the credit industry by providing a comprehensive solution that enhances customer experience and accessibility to credit, integrating seamlessly into its network of partners through a proprietary API. The company primarily generates its revenue from the United States.

OrCam

Venture Round in 2018
OrCam is a developer and manufacturer of portable artificial vision devices aimed at assisting individuals with visual impairments. The company has created an innovative device that combines a miniature video camera and a processing unit, which can be discreetly attached to eyeglasses. This device utilizes advanced computer vision algorithms to recognize text and identify objects, enabling users to receive auditory feedback through a discreet earpiece. By vocalizing text from various sources, such as street signs, menus, and books, OrCam’s technology enhances the daily lives of those with vision loss, allowing them to interact more easily with their surroundings.

Carr Properties

Debt Financing in 2018
Carr Properties is a privately held real estate investment trust specializing in the ownership, acquisition, and development of high-quality office properties primarily in the greater Washington area. The company currently owns 16 commercial office properties encompassing over 3.6 million square feet, alongside three significant development projects: Midtown Center in Washington, DC, 2311 Wilson Boulevard, and 2025 Clarendon Boulevard, both in Arlington, Virginia. Once completed, these developments will contribute an additional 1.25 million square feet of prime office space to its portfolio. Carr Properties is committed to expanding its holdings through strategic investments in the Washington area, Boston, and Austin, focusing on enhancing value for its shareholders.

Compugen

Venture Round in 1998
Compugen Ltd. is a clinical-stage therapeutic discovery and development company based in Holon, Israel, focused on immuno-oncology. The company leverages its advanced computational discovery capabilities to identify novel drug targets and biological pathways, leading to the development of therapeutics for cancer treatment. Compugen's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, a therapeutic antibody targeting TIGIT, both of which are in Phase I clinical studies for solid tumors. Additionally, the company is exploring early-stage programs aimed at addressing various mechanisms of immune resistance. Compugen has established collaborations with notable organizations, including Bayer Pharma AG and Bristol-Myers Squibb, for the research and development of antibody-based therapeutics. The company's innovative approach combines in silico prediction with experimental validation, allowing it to address critical therapeutic and diagnostic needs in the pharmaceutical and biotech sectors. Compugen was incorporated in 1993 and continues to advance its research and development efforts in the field of cancer immunotherapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.